



Guide d'instructions : AIDS 2020 Knowledge Toolkits

Ce guide d'instructions donne un aperçu de la navigation dans les outils de connaissances AIDS 2020. IAS – l'International AIDS Society – a développé un ensemble d'outils afin de répondre à un objectif essentiel, celui d'investir dans la main-d'œuvre du VIH en développant les compétences et les connaissances nécessaires pour mettre fin à l'épidémie.

L'ensemble complet propose 18 boîtes à outils téléchargeables créées exclusivement pour les membres de l'IAS afin de mieux accéder et utiliser les dernières avancées de la recherche scientifique présentées à la 23e Conférence internationale sur le sida (*AIDS 2020: Virtual*).

CE QUI EST INCLU

Cliquez sur le lien sur le site Web pour télécharger automatiquement chaque boîte à outils par domaine thématique.


Chaque ensemble individuel comprend la présentation PowerPoint pour ce domaine avec les notes du conférencier correspondantes.

LA NAVIGATION

Une fois téléchargées, les présentations ont été conçues pour permettre une navigation rapide vers des sujets spécifiques, des études, des populations et plus encore.



La diapositive "Vue d'ensemble" (diapositive trois dans tous les ensembles) comprend des boutons qui pointent vers des sujets spécifiques dans la présentation. Veuillez noter que toutes les fonctions doivent être exécutées à partir du mode "diaporama". Pour revenir à la diapositive "Vue d'ensemble", cliquez sur le logo IAS dans le coin supérieur gauche de n'importe quelle diapositive. Voir l'exemple ci-dessous.



IAS **Libération prolongée**
Opportunités et défis dans le domaine des formulations à libération prolongée (LP)

The challenge: Need to accelerate pipeline for application to pediatric medicines

LONGER-TERM (7 yrs)	MEDIUM-TERM (3 – 6 yrs)	NEAR-TERM (1 – 2 yrs)
Needle-free syringes	Oral films	Injectable tablets (ITs)
Microspheres	Long-acting oral products	Oral-dispersible tablets (ODTs)
	Long-acting implants *	Multi-particulates (MPs)
	3D Printing	Microbubbles (3.0 min)
		Long-acting Depot Injections *
		Suppositories
		3D-printing technologies
		Enhanced bioavailability

The challenge: economic considerations for long-acting technologies expanded access in LMICs

End user

- Is the product affordable compared to existing care?
- If more expensive, how much more expensive?
- What are the risks and benefits as it relates to price compared to existing care?
- Is there positive impact on work or income related to this within the health system and increased efficiency?

Health Care Provider

- Depending on product administration requirements, are there savings to HR resources or additional costs?
- Are there additional supplies or ancillary costs that are required to use (and dispense) the product (e.g., syringes)?
- Will the product and care be covered by insurance?

Deployment

- What proportion of the population would need to access the long-acting tool?
- Is this a replacement product or new tool in health system?
- Given the price of the product per unit, would there be deficits to the existing procurement budget?
- Long term implications for budget?

Investment case

- Is the product affordable in the response in LMICs?
- If the product purchasing cost is expected to be higher than current standard of care, are there **cost savings** to the health system?
- What is the return on investment?
 - For treatment: Increased population with viral suppression → decreased partner transmission & decreased risk of resistance?
 - For prevention → decreased number of infections?
- How does the product contribute to meeting targets?

Unitaid, Trust for Africa

Carmen Perez Casas

RÉFÉRENCES ET SOURCES

Les références fournies dans le coin inférieur droit de chaque diapositive renvoient aux sources pertinentes de la conférence (par exemple, résumés des résumés, diapositives de présentation ou enregistrements vidéo). Voir l'exemple ci-dessous.

IAS Libération prolongée
Opportunités et défis dans le domaine des formulations à libération prolongée (LP)

The challenge: Need to accelerate pipeline for application to pediatric medicines

LONGER TERM (7 yrs) | **MEDIUM-TERM (3 - 4 yrs)** | **NEAR-TERM (2 - 2 yrs)**

Injectable long-acting | Oral films | Depository systems (DPS)
Microencapsules | Long-acting implants* | Multi-particulate (DMS)
3-D Printing | Intravitreal (IVT)
Long-acting eluent systems* | Sustained-release emulsions
New-releasing technologies | Subcutaneous bioresorbable

Legend:
No data for age appropriateness
Available products in LMICs
Long-acting products
Pediatric contains only application for older ages

The challenge: economic considerations for long-acting technologies expanded access in LMICs

Value

- Is the product affordable compared to existing care?
- If cost expensive, how much more expensive?
- What are the risk and benefits as it relates to access compared to existing care?
- Is there positive impact on work or income related to less visits to the health system and increased effectiveness?

Health Care Provider

- Depending on product administration requirements, are there savings to the resources or additional costs?
- Are there additional expenses or product costs that are required to use and dispose the product (i.e., syringes)?
- Will the product and care be covered by insurance?

Investment case

- Is the product affordable in the response in LMICs?
- If the product purchasing cost is expected to be higher than current standard of care, are there cost savings to the health system?
- What is the return on investment?
 - For treatment: increased population with viral suppression → decreased partner transmission & decreased risk of resistance?
 - For prevention → decreased number of infections?
- How does the product contribute to meeting targets?

Carmen Perez Casas

CONTACT

Veillez contacter les services aux membres de l'IAS, à memberservice@iasociety.org pour toute question ou commentaire.